Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 9/20 | 0.35 |
| ▸ | BCHE | P06276 | 4/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13691569 | 0.84 | GBA1 (0.40) | FUCA1S1PR1S1PR5ACHEBCHE | |
| SCHEMBL51682 | 0.80 | BCHE (0.36) | FUCA1S1PR1S1PR5ACHEBCHE | |
| SCHEMBL62328 | 0.80 | BCHE (0.36) | FUCA1S1PR1S1PR5ACHEBCHE | |
| SCHEMBL4058697 | 0.77 | GBA1 (0.47) | FUCA1S1PR1S1PR5ACHEBCHE | |
| SCHEMBL27704477 | 0.72 | FUCA1 (0.55) | FUCA1S1PR1S1PR5ACHE | |
| SCHEMBL27783471 | 0.72 | HRH3 (0.53) | FUCA1S1PR1S1PR5ACHE | |
| SCHEMBL27783472 | 0.72 | HRH3 (0.53) | FUCA1S1PR1S1PR5ACHE | |
| SCHEMBL13107603 | 0.69 | CCR3 (0.49) | ACHEBCHE | |
| SCHEMBL13221838 | 0.69 | CCR3 (0.49) | ACHEBCHE | |
| SCHEMBL13003723 | 0.66 | CCR3 (0.55) | ACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129398-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| WO-2009117540-A1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253677-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | FUCA1 2329/4885S1PR1 4182/4885S1PR5 4454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.